6 results about "Neural Growth" patented technology

In one aspect, methods of promoting asymmetric nerve growth and / or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The invention discloses an application of a non-traditional myosin IF gene MYO1F in preparation of a peripheral nerve growth regulation and control medicine. The invention proposes and verifies that the expression of the non-traditional myosin IF gene MYO1F can effectively regulate and control the physiological activity of neurons of a peripheral nervous system for the first time, for example, the expression of the MYO1F is inhibited to effectively inhibit the proliferation and migration of Schwann cells; the invention provides a new direction for research and development of drugs for treating Schwann cell-derived diseases and diseases caused by nerve injury.

The invention discloses application of fibroblasts in preparation of a medicine for inhibiting nerve cell growth, and belongs to the technical field of biological medicine. Researches find that the fibroblasts can inhibit proliferation and differentiation of neural progenitor cells in vitro and also can inhibit growth of mature nerve cells, and obvious inhibition of nerves can be observed in an in-vivo mouse intervertebral disc degeneration model, so that the fibroblasts can be used for inhibiting abnormal ingrowth of nerves in the intervertebral disc degeneration process and relieving intervertebral disc degeneration.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

This invention discloses a neurofilament light chain protein derivative, biomaterial, and its applications. The neurofilament light chain protein derivative is a protein based on the neurofilament light chain protein or its homologous protein with the sequence shown in SEQ ID NO: 1, wherein one or more amino acid residues in the Coil 2B region have pharmaceutically acceptable modifications or mutations. This invention designs and constructs a neurofilament light chain protein K316Q mutant by acetylation-mimicking mutation of the neurofilament light chain protein, which exhibits significant effects in promoting nerve growth and regeneration. This mutant can enhance the stability and function of neurofilament networks, promote the expansion of axonal growth cones, and directly target the intrinsic growth capacity of neurons, demonstrating excellent clinical translational potential.